Reuters: Bill Smead on Merck Sales Forecast for 2023

Merck raises 2023 sales forecast as top drugs beat Street estimates

By Michael Erman and Leroy Leo

For more information go to reuters.com.

Stocks mentioned: MRK

The information contained in this tv appearance represents SCM’s opinions, and should not be construed as personalized or individualized investment advice. Past performance is no guarantee of future results. The securities identified and described in this tv appearance do not represent all of the securities purchased or recommended for our clients. It should not be assumed that investing in these securities was or will be profitable. A list of all recommendations made by Smead Capital Management with in the past twelve month period is available upon request.

We Advise Investors

Recent Missives

Tech Stock Climax

June 18, 2026

In my 45 years in the investment business, we've observed numerous peaks of excitement. In 1987, a bull market that started at a 1982 bottom below 800 on the Dow Jones Industrial Average...

⟶ Keep Reading

CNBC Europe Squawk Box: Cole Smead on SpaceX Valuation’s Impact

June 10, 2026

SpaceX is already targeting a mammoth valuation. Will passive funds take it even higher? Squawk Box Europe hosted by Stephen Sedgwick For more information go to www.cnbc.com. […]

⟶ Keep Reading

Business Insider: Bill Smead on Being Bullish on Commodities

June 5, 2026

History says there’s one hedge that could shelter investors during a lost decade for stocks By Jennifer Sor For more information go to www.businessinsider.com. The information contained in this […]

⟶ Keep Reading

Late-Stage Mania: “The Worst Thing Ever”

June 4, 2026

There is a big difference between betting on something and investing in meritorious companies with long holding periods. Although we are no longer shareholders of Berkshire Hathaway, Warren Buffett shared some wisdom with...

⟶ Keep Reading